Lyell Immunopharma, Inc.
LYEL Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$9.39
KIRA · Stoqly’s AI analyst, in plain words
- Lyell Immunopharma, Inc. had $0.0M of revenue in fiscal 2025, down 41.0% on the year before. Over five years, revenue changed −65.9% a year on average.
- Its operating margin was −748,344.4%, down 160,221.5 pts: of every 100 in sales, about −748,344 is left after running the business.
- Lyell Immunopharma, Inc. lost $274M in fiscal 2025.
- Free cash flow was −$151M in fiscal 2025, −418,900.0% of revenue.
Market cap
$219M
P/E
—
Revenue
$0.0M
Net income
−$274M
Free cash flow
−$151M
Operating margin
−748,344.4%
Lyell Immunopharma, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−41.0%
No. Sales fell 41.0% last year.
Does it make a profit?
−762,355.6%
No. It lost money last year.
Does profit turn into cash?
−418,900.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lyell Immunopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Lyell Immunopharma, Inc.
- CIK
- 0001806952
Lyell Immunopharma, Inc. · LYEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.7M | $84.7M | $0.1M | $0.1M | $0.0M |
| Revenue growth | 37.3% | 695.1% | −99.8% | −53.1% | −41.0% |
| Operating margin | −2,016.7% | −220.9% | −190,006.2% | −588,123.0% | −748,344.4% |
| Net income | −$250M | −$183M | −$235M | −$343M | −$274M |
| Net margin | −2,349.5% | −216.2% | −180,486.2% | −562,285.2% | −762,355.6% |
| Diluted EPS | −$1.84 | −$0.74 | −$18.70 | −$26.23 | −$16.06 |
| Cash | |||||
| Cash from operations | −$126M | −$170M | −$164M | −$162M | −$150M |
| Capital expenditure | $65.5M | $24.3M | $2.7M | $0.5M | $0.8M |
| Free cash flow | −$192M | −$194M | −$166M | −$163M | −$151M |
| FCF margin | −1,800.5% | −228.9% | −127,984.6% | −266,980.3% | −418,900.0% |
| Share buybacks | $0.0M | $0.0M | — | — | — |
| Share count change | 925.2% | 81.8% | −94.9% | 4.2% | 30.7% |
| Debt and strength | |||||
| Cash and short-term investments | $615M | $640M | $546M | $371M | $247M |
| Shareholders' equity | $930M | $833M | $655M | $383M | $248M |
| Current ratio | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Returns and quality | |||||
| Return on equity | −78.5% | −20.8% | −31.5% | −66.1% | −87.0% |
| Return on tangible equity | −26.9% | −22.0% | −35.8% | −89.6% | −110.6% |
| Piotroski F-score | 4 | 4 | 2 | 1 | 1 |
| Altman Z'' | 5.3 | 8.7 | 5.2 | −5.8 | −13.9 |
Insiders bought, 12 months
$12.5M
1 insider
Insiders sold, 12 months
$0.6M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lyell Immunopharma, Inc. · LYEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.39 a share, the company is worth $219M.
Source: SEC EDGAR XBRL filings (CIK 0001806952). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.